Feature Channels: Pharmaceuticals

Filters close
Released: 1-Nov-2022 4:00 PM EDT
FDA Approves Oral MEK Inhibitor Cobimetinib for Histiocytic Neoplasms, Research Led by Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms (HN). These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2, currently approved to treat melanoma.

Released: 1-Nov-2022 9:05 AM EDT
Light of Transformation: Research Explores the Inner Workings of Chemical Change
Binghamton University, State University of New York

Binghamton University Assistant Professor of Chemistry Jennifer Hirschi recently received a Maximizing Investigators’ Research Award for $1.93 million from the National Institute of General Medical Sciences to study the mechanisms involved in catalytic reactions.

25-Oct-2022 2:05 PM EDT
Apixaban associated with lower risk of GI bleeding compared to all DOACs
American College of Physicians (ACP)

A multinational cohort study of persons with atrial fibrillation (AF) found that compared with all direct oral anticoagulants (DOACs), apixaban was associated with lower rates of gastrointestinal (GI) bleeding but similar rates of ischemic stroke, intracranial hemorrhage (ICH), and all-cause mortality. The findings are published in Annals of Internal Medicine.

25-Oct-2022 2:05 PM EDT
Ticagrelor–aspirin antiplatelet therapy more beneficial in persons with normal renal function
American College of Physicians (ACP)

An analysis of the CHANCE-2 trial has found that persons with normal renal function receive greater benefit from antiplatelet therapy with ticagrelor–aspirin versus clopidogrel–aspirin. The analysis is published in Annals of Internal Medicine.

25-Oct-2022 2:05 PM EDT
Urine bicarbonate test offers new, safe quantification of CFTR function in cystic fibrosis patients
American College of Physicians (ACP)

A study of 50 adult patients with cystic fibrosis (CF) has found that challenged urine bicarbonate excretion may offer a new, simple, and safe quantification of cystic fibrosis transmembrane conductance regulator (CFTR) function and the extent of its pharmacologic improvement. The study is published in Annals of Internal Medicine.

Newswise: Treated or Not, COVID-19 Recurrence Seems Symptomatic for Some
Released: 31-Oct-2022 12:10 PM EDT
Treated or Not, COVID-19 Recurrence Seems Symptomatic for Some
University of California San Diego

UC San Diego researchers and others report that more than one-third of the COVID-19 patients who did not receive any treatment experienced complete resolution of symptoms for at least two consecutive days, but then subsequently reported a return of symptoms.

Released: 31-Oct-2022 12:05 PM EDT
Industry payments to physicians and advanced practice clinicians compared
Duke Health

A new study led by Duke Health found that advanced practice clinicians received more payments from drug companies, while physicians accepted more funds from medical device companies. The same proportion of each group accepted payments, but the physicians received a much greater sum.

Released: 31-Oct-2022 10:05 AM EDT
Members of Congress Call for CRNA Full Practice Authority Approval In VA
American Association of Nurse Anesthesiology

To expand access to safe, high-quality anesthesia services to veterans, Rep. Lauren Underwood (IL-D) along with 12 Congressional colleagues requested that CRNAs be granted full practice authority permanently across VA facilities.

Newswise: Breast Cancer Drug Benefits Broader Group of Patients, Trial Shows
Released: 31-Oct-2022 9:05 AM EDT
Breast Cancer Drug Benefits Broader Group of Patients, Trial Shows
UT Southwestern Medical Center

A drug approved to treat breast cancer patients with mutations in the BRCA1 or BRCA2 genes may also benefit people who have other genetic mutations.

Newswise: Ludwig Chicago Nanotechnology Induces Therapeutic Immune Responses Against Multiple Types of Tumors
Released: 28-Oct-2022 11:30 AM EDT
Ludwig Chicago Nanotechnology Induces Therapeutic Immune Responses Against Multiple Types of Tumors
Ludwig Cancer Research

A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers.

   
Released: 28-Oct-2022 8:05 AM EDT
ScienceMedia Joins Forces with Leading Advocate for Life Sciences in California
ScienceMedia

ScienceMedia has joined Biocom California at the Provider level of membership, connecting to more than 1,700 member companies and 500,000 employees across California and beyond.

   
Released: 28-Oct-2022 3:05 AM EDT
Study Reveals How Naturally-Occurring Compound Kills Major Drug-Resistant Bacteria
University of Portsmouth

Researchers say hydroquinine could be an effective weapon against a germ that can cause serious infections in humans, mostly hospital patients.

Newswise: University of Kentucky Researchers Create New Cancer Fighting Compound
Released: 27-Oct-2022 3:20 PM EDT
University of Kentucky Researchers Create New Cancer Fighting Compound
University of Kentucky

A University of Kentucky Markey Cancer Center researcher’s team developed new chemical compounds that show promise as a potential anticancer therapy to treat aggressive tumors. The study led by Samuel G. Awuah, Ph.D., was published in Chemical Communications with Adedamola Arojojoye, a graduate student in Awuah’s lab as the paper’s first author.

Newswise: Yale Cancer Center Researchers Discover Differences in Response for Endometrial Cancer Treated with Pembrolizumab
Released: 27-Oct-2022 10:45 AM EDT
Yale Cancer Center Researchers Discover Differences in Response for Endometrial Cancer Treated with Pembrolizumab
Yale Cancer Center/Smilow Cancer Hospital

New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.

Released: 26-Oct-2022 2:40 PM EDT
Donald E. Arnold, M.D., FASA, elected First Vice President of the American Society of Anesthesiologists
American Society of Anesthesiologists (ASA)

Donald E. Arnold, M.D., FASA, was today elected as first vice president of the American Society of Anesthesiologists (ASA), the nation’s largest organization of physician anesthesiologists. Dr. Arnold was elected by the House of Delegates at the ANESTHESIOLOGY® 2022 annual meeting and will serve for one year.

11-Oct-2022 12:00 PM EDT
American Society of Anesthesiologists honors James D. Grant, M.D., MBA, FASA, with its Distinguished Service Award
American Society of Anesthesiologists (ASA)

The American Society of Anesthesiologists (ASA) today presented James D. Grant, M.D., MBA, FASA, with its 2021 Distinguished Service Award in recognition of his highly distinguished career as a physician anesthesiologist, enduring contributions to ASA members and deep commitment to advocating for the specialty and protecting patient safety.

11-Oct-2022 12:00 PM EDT
American Society of Anesthesiologists names Michael W. Champeau, M.D., FASA, new president
American Society of Anesthesiologists (ASA)

American Society of Anesthesiologists names Michael W. Champeau, M.D., FASA, new president

Newswise: Popular Pharmaceutical Target in Cells May Prove Even More Useful
Released: 26-Oct-2022 12:00 PM EDT
Popular Pharmaceutical Target in Cells May Prove Even More Useful
University of California San Diego

Researchers at UC San Diego have identified a new signaling process involving G protein-coupled receptors (GPCRs), a cellular target already exploited by hundreds of diverse drugs. The discovery opens the possibility of new therapies, including for multiple forms of cancer.



close
3.26973